



SUPRIYA LIFESCIENCE LTD.

Creating true values that bind global health

Date: January 21, 2022

To,

The Corporate Services Department, Bombay Stock Exchange Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400 001 Scrip Code: 543434	Manager - Listing Department The National Stock Exchange of India Ltd. Exchange Plaza, Plot no. C/1, G Block, Bandra-Kurla Complex Bandra (E), Mumbai - 400 051 NSE Symbol: SUPRIYA
---	--

Dear Sir/Madam,

Subject: PRESS RELEASE- UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED DECEMBER 31, 2021

The Board of Directors of the Company at their Meeting held on January 21, 2022 has inter alia, considered and approved the Un-Audited Standalone Financial Results for the Quarter ended December 31, 2021.

Please find attached the Press Release with regard to the Un-Audited Financial Results of the Company for the quarter and half year ended December 31, 2021.

You are requested to kindly take the same on record.

Thanking you,

For Supriya Lifescience Ltd

Shweta Singh
Company Secretary & Compliance Officer
Membership No.: A44973



Corporate Office : 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai 400 063. Maharashtra, India.

Tel : +91 22 40332727 / 66942507 | Fax : +91 22 26860011

CIN: U51900MH2008PLC180452 | E-mail: supriya@supriyalifescience.com | Website: www.supriyalifescience.com

Factory

: A-5/2, Lote Parshuram Industrial Area, M.I.D.C., Tal.- Khed, Dist.- Ratnagiri, Pin: 415 722, Maharashtra, India.

Tel: +91 2356 272299 | Fax : +91 2356 272178 | E-Mail: factory@supriyalifescience.com

GOVT. RECOGNISED EXPORT HOUSE



SUPRIYA LIFESCIENCE LTD.

Supriya Lifescience Limited

Key Consolidated Highlights for Q3 FY22

Revenue growth of 44% YoY to Rs.1,224.4 million

EBITDA stood at Rs. 438.2 million with EBITDA margin of 36%

PAT stood at Rs. 396.4 million with PAT margin of 32%

Investor Release (21st January 2022): . Supriya Lifescience Ltd. a cGMP compliant company having a well established presence in API Manufacturing with focus in products of various therapeutic segments like - Anti-Histamine, Anti-Allergics, Vitamins, Anaesthetics, Anti-Asthmatics etc. has declared its Un-audited financial statements for the Quarter and 9 Month ended 31st December 2021

Key Consolidated Financial Highlights:

Particulars	Q3 FY22	Q3 FY21	9M FY22	FY21
Revenues (in INR Mn)	1,224.4	850.2	3,525.0	3,962.2
EBITDA (in INR Mn)	438.2	301.6	1,424.8	1,781.5
EBITDA Margins (%)	36%	35%	40%	45%
PAT (in INR Mn)	396.4	156.9	1056.0	1238.3

Key Highlights for Q3FY22:

Consolidated Revenue for Q3FY22 reported a growth of **44 % (YoY)** to Rs. 1,224.4 million as compared to Rs. 850.2 million in Q3FY21.

The current quarter performance was driven by very strong demand for anaesthetic, Anti-asthmatic and Vitamin therapy. The company expects the demand for these therapies to be strong, also expect demand for antihistamine to pick up going forward.

Increase in Q3 sales was also driven by higher penetration in regulated markets like Europe and Latin America

Gross Profit for Q3 FY22 stood at Rs. 806.5 million as compared to Rs. 522.7 million in Q3 FY21 , a growth of **54%** compared to same quarter last year.

EBITDA for Q3 FY22 stood at Rs. 438.2 million and EBITDA Margin stood at 36% as against Rs. 301.6 million in Q3 FY21 (35%), registering a growth of **45% (YoY)**

PAT for Q3 FY22 stood at Rs. 396.4 million and PAT Margin stood at 32 % in Q3 FY21 as against Rs. 156.9 million in Q3FY21, registering a growth of **153%**.



SUPRIYA LIFESCIENCE LTD.

Unique positioning & Key Growth Drivers:

- **Significant scale with leadership position across key & niche products**
 - Niche product offerings of 38 APIs with demonstrated ability to develop & scale-up production
 - Diversified therapeutic categories
 - Large percentage of exports from India in the top three products i.e chlorpheniramine maleate, ketamine hydrochloride and salbutamol sulphate
- **Backward integrated business model**
 - Fully backward integrated company which gives protection against market fluctuation, Lesser dependence on external parties, Steady supply of essential raw materials
- **Geographically diversified revenues with a global presence across 86 countries**
 - More focus on penetration into regulated markets where we get better average selling price of our existing products
- **Advanced manufacturing and research and development capabilities**
 - 4 manufacturing blocks in operation with 7 clean rooms.
 - Focus on uniform manufacturing standards to achieve standardised product quality across markets
- **Experienced senior management team and qualified operational personnel**
 - Strong board of directors
 - Robust independent board of directors from different sectors
 - Strong second line

Commenting on the Results, Dr. Satish Wagh, Chairman & Managing Director, Supriya Lifescience said.

“I would like to thank everyone for the overwhelming support we have received for our IPO. With this support and trust from the investors our IPO was oversubscribed by 71.47 times.

The company has shown consistent performance for 9 months FY22 with an operating revenue of Rs 3,525.0 Mn with EBIDTA of Rs 1,424.8 Mn (40 % of Revenue) and PAT of Rs 1,056.0 Mn (30% of revenue). The current quarter performance was driven by very strong demand for anaesthetic, anti-asthmatic and Vitamin products.

The fourth manufacturing block at our site got operational in May'21. We have also commenced the work for the next manufacturing block which is expected to get operational by FY23. This block will add 310 KL capacity. Two new warehouses for Finished Goods and Raw materials will get operational by Q1 FY23. A new Quality Control laboratory along with state-of-the-art R&D laboratory will be operational by Q2 FY23.

In line with company strategy to penetrate in more regulated markets, we have also applied for registering more products in US, European and Chinese markets “



SUPRIYA LIFESCIENCE LTD.

About Supriya Lifescience Limited

Established in the year 1987, Supriya Lifescience Ltd. is a global leading manufacturer of Active pharmaceutical Ingredients. The company was founded by Dr. Satish Wagh, a first-generation entrepreneur and technocrat. Armed with technical knowledge, business acumen and an extensive experience of more than 35 years in the pharmaceutical industry, he has been instrumental for what Supriya Lifescience Ltd is today. Company is leader in Therapeutic Segments like Anti-Histamines, Anti-Allergic, Anti-Asthmatics, Anesthetic & Vitamins. Supriya Lifescience Ltd has State-of-the-art manufacturing facility is certified by USFDA, EDQM, EUGMP, NMPA & Health Canada. Facility is located in Khed, District Ratnagiri and headquartered in Mumbai, India.

Safe Harbor

Any forward-looking statements about expected future events, financial and operating results of the Company are based on certain assumptions which the Company does not guarantee the fulfilment of. These statements are subject to risks and uncertainties. Actual results might differ substantially or materially from those expressed or implied. Important developments that could affect the Company's operations include a downtrend in the industry, global or domestic or both, significant changes in political and economic environment in India or key markets abroad, tax laws, litigation, labour relations, exchange rate fluctuations, technological changes, investment and business income, cash flow projections, interest and other costs. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.

Company:

Investor Relations Advisors:



SUPRIYA LIFESCIENCE LTD.

Supriya Lifescience Limited

CIN: U51900MH2008PLC180452

Mr. Ashish Nayak

Chief Financial Officer

cfo@supriyalifescience.com



Orient Capital (a division of Link Group)

Mr. Rajesh Agrawal

+91 99674 91495

rajesh.agrawal@linkintime.co.in

Ms. Rasika Sawant

+91 9594457518

rasika.sawant@linkintime.co.in
